Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Sarb99on Nov 23, 2020 10:31pm
145 Views
Post# 31958199

RE:RE:QuestCap is on the path be become an example

RE:RE:QuestCap is on the path be become an example
US federal GOVT will be paying for vaccines and the biggest challenge for them going to be distribution. I think this is how it going to work, no one gets a contract until vaccine is widely available then GOVT can approach companies in this field or companies will approach federal GOVT and sign contract. 
 
Any company that wants to offer this service needs to prove; they have an infrastructure set up to vaccinate people. QuestCap with 1000-2000 locations should have no problem to get this contract. Where else a GOVT going to find 1000-2000 locations setup and that too in busy locations like shopping malls. Plus, by then QuestCap should be a proven company in the medical field related to covid-19 testing. They should also have data compiled from all the customers getting tested for covid-19.
 
QuestCap is changing its name for a reason. “QuestCap” does not relate to the medical services name, so they are changing the company name, to something that relates to the medical service field. Once they start filing paper works to get contracts, the name should relate to medical services. 

Coronavirus testing probably be needed until 70-80% are vaccinated worldwide. Further study should be needed to see vaccine is working. Once people get vaccine, they are safe, not spreading covid-19. People cannot turn blind eye once they are vaccinated as there is no study right now to see how effectively vaccine work and how long it protects you. 
 
Once this pandemic is over, they can add in vitro diagnostics testing service, flu shot, antibody tests, PCR test and of course covid-19 vaccination every year. 

optex1972 wrote:

 

Sarb99 wrote: As picture posted on https://twitter.com/quest_cap/status/1330914848155242499 people waiting in the lineup to get tested. We can also see on collection sites appointment system. Most of these collection sites are remarkably busy performing covid-19 testing. QuestCap is already generating revenue compare to many others. QuestCap is also have a plan for testing, then vaccination then life after pandemic.  
 
Here is math, not pumping, I am even under estimating compare to those lineups and appointment system. I am going to say each collection site perform 125 test each day. 22x125 total daily test performed 2750. Now QuestCap charge $59 for Antibody, $99 for antigen then $179 for PCR, which is needed for travel. We will just pick average $75 per test.
 
2750x$75 =$206,250 daily revenue and $6,187,500 per month and $74 million per year.
 
If you calculate each site perform 150 test each day or some even 170 then these revenue number should be higher. Now lets say by the end of December QuestCap install 416+ testing sites then these revenue numbers are huge. As most us brought QSC under $.20 cents, I think reward for us can be huge.
 
As per our risk, revenue from these 22 sites of $74.25 million with 50% profit margin is $37.12 million and we can easily time it by 5. So, market cap with alone with these 22 sites should be somewhere $150 to $185 Million. So, at these prices, we are taking no risk other than wait. 

 

 

thanks sarb for the detail! Only question I have now is I wonder what "pen to paper" process has been done as of today for "post testing" as far as agreements in administering Vaccine and such and who those are done with? Ie: government, individual states, what authorities? Kinda thing..

 



<< Previous
Bullboard Posts
Next >>